よむ、つかう、まなぶ。
07 参考資料２－１ 帯状疱疹ワクチン ファクトシート (47 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_36248.html |
| 出典情報 | 厚生科学審議会 予防接種・ワクチン分科会 予防接種基本方針部会 ワクチン評価に関する小委員会（第21回 11／9）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
58. Williams V, Gershon A, Brunell PA. Serologic response to varicella-zoster membrane
antigens measured by direct immunofluorescence. J Infect Dis 1974 ;130: 669-72.
59. Wasmuth EH, Miller WJ. Sensitive enzyme-linked immunosorbent assay for antibody to
varicella-zoster virus using purified VZV glycoprotein antigen. J Med Virol 1990; 32:
189-93.
60. Baba K, Yoshida M, Tawa A, Yabuuchi H, Maeda K, Takahashi M. A simplified
immunofluorescence technique for antibody to varicella-zoster membrane antigen (FAMA).
Biken J 1984 ; 27:23-9.
61. Sauerbrei A, Färber I, Brandstädt A, Schacke M, Wutzler P. Immunofluorescence test for
sensitive detection of varicella-zoster virus-specific IgG: an alternative to fluorescent
antibody to membrane antigen test. J Virol Methods 2004;119:25-30.
62. Dobec M, Bossart W, Kaeppeli F, Mueller-Schoop J.
Serology and serum DNA detection
in shingles. Swiss Med Wkly 2008; 138: 47-51
63. Otani N., Baba K., Okuno T. Interferon-gamma release assay: a simple method for
detection of varicella-zoster virus-specific cell-mediated immunity. J Immunol Methods
2009; 351: 71-4.
64. Salem Fourati I, Grenier AJ, Jolette É, Merindol N, Ovetchkine P, Soudeyns H.
Development of an IFN-gamma ELISpot assay to assess varicella-zoster virus-specific
cell-mediated immunity following umbilical cord blood transplantation. J Vis Exp
2014 ;(89). doi: 10.3791/51643.
65. Asano Y, Shiraki K, Takahashi M, Nagai H, Ozaki T, Yazaki T.
Soluble skin test antigen
of varicella-zoster virus prepared from the fluid of infected cultures. J Infect Dis 1981; 143:
684-92.
66. Wood MJ, Kay R, Dworkin RH, Soong SJ, Whitley RJ. Oral acyclovir therapy accelerates
pain resolution in patients with herpes zoster: a meta-analysis of placebo-controlled trials.
Clin Infect Dis 1996; 22: 341-7.
67. Jackson JL, Gibbons R, Meyer G, Inouye L. The effect of treating herpes zoster with oral
acyclovir in preventing postherpetic neuralgia. A meta-analysis. Arch Intern Med 1997;
157: 909-12.
68. Crooks RJ, Jones DA, Fiddian AP. Zoster-associated chronic pain: an overview of clinical
trials with acyclovir. Scand J Infect Dis Suppl. 1991; 80: 62-8.
69. Huff JC, Drucker JL, Clemmer A, Laskin OL, Connor JD, Bryson YJ, Balfour HH Jr.
Effect of oral acyclovir on pain resolution in herpes zoster: a reanalysis. J Med Virol 1993;
Suppl 1:93-6.
70. Morton P, Thomson AN. Oral acyclovir in the treatment of herpes zoster in general practice.
N Z Med J 1989; 102: 93-5.
42
antigens measured by direct immunofluorescence. J Infect Dis 1974 ;130: 669-72.
59. Wasmuth EH, Miller WJ. Sensitive enzyme-linked immunosorbent assay for antibody to
varicella-zoster virus using purified VZV glycoprotein antigen. J Med Virol 1990; 32:
189-93.
60. Baba K, Yoshida M, Tawa A, Yabuuchi H, Maeda K, Takahashi M. A simplified
immunofluorescence technique for antibody to varicella-zoster membrane antigen (FAMA).
Biken J 1984 ; 27:23-9.
61. Sauerbrei A, Färber I, Brandstädt A, Schacke M, Wutzler P. Immunofluorescence test for
sensitive detection of varicella-zoster virus-specific IgG: an alternative to fluorescent
antibody to membrane antigen test. J Virol Methods 2004;119:25-30.
62. Dobec M, Bossart W, Kaeppeli F, Mueller-Schoop J.
Serology and serum DNA detection
in shingles. Swiss Med Wkly 2008; 138: 47-51
63. Otani N., Baba K., Okuno T. Interferon-gamma release assay: a simple method for
detection of varicella-zoster virus-specific cell-mediated immunity. J Immunol Methods
2009; 351: 71-4.
64. Salem Fourati I, Grenier AJ, Jolette É, Merindol N, Ovetchkine P, Soudeyns H.
Development of an IFN-gamma ELISpot assay to assess varicella-zoster virus-specific
cell-mediated immunity following umbilical cord blood transplantation. J Vis Exp
2014 ;(89). doi: 10.3791/51643.
65. Asano Y, Shiraki K, Takahashi M, Nagai H, Ozaki T, Yazaki T.
Soluble skin test antigen
of varicella-zoster virus prepared from the fluid of infected cultures. J Infect Dis 1981; 143:
684-92.
66. Wood MJ, Kay R, Dworkin RH, Soong SJ, Whitley RJ. Oral acyclovir therapy accelerates
pain resolution in patients with herpes zoster: a meta-analysis of placebo-controlled trials.
Clin Infect Dis 1996; 22: 341-7.
67. Jackson JL, Gibbons R, Meyer G, Inouye L. The effect of treating herpes zoster with oral
acyclovir in preventing postherpetic neuralgia. A meta-analysis. Arch Intern Med 1997;
157: 909-12.
68. Crooks RJ, Jones DA, Fiddian AP. Zoster-associated chronic pain: an overview of clinical
trials with acyclovir. Scand J Infect Dis Suppl. 1991; 80: 62-8.
69. Huff JC, Drucker JL, Clemmer A, Laskin OL, Connor JD, Bryson YJ, Balfour HH Jr.
Effect of oral acyclovir on pain resolution in herpes zoster: a reanalysis. J Med Virol 1993;
Suppl 1:93-6.
70. Morton P, Thomson AN. Oral acyclovir in the treatment of herpes zoster in general practice.
N Z Med J 1989; 102: 93-5.
42